DAF/CD55 and Protectin/CD59 modulate adaptive immunity and disease outcome in experimental autoimmune myasthenia gravis

Journal of Neuroimmunology

Volumn 244, Issue 1-2, 2012, Pages 63-69

  Soltys, Jindrich ^a   Halperin, Jose A ^b,c   Xuebin, Qin ^b,c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acetylcholine receptor (AChR); Decay accelerating factor (DAF CD55); Experimental autoimmune myasthenia gravis (EAMG); Humoral and adaptive immune response; Protectin (CD59); Regulators of complement activity (RCA)

Indexed keywords

CD59 ANTIGEN; CD97 ANTIGEN; CHOLINERGIC RECEPTOR; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; CYTOKINE; DECAY ACCELERATING FACTOR; REGULATOR PROTEIN;

ADAPTIVE IMMUNITY; ANTIBODY DETECTION; ANTIGEN SPECIFICITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNOMODULATION; MOUSE; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, CD55; ANTIGENS, CD59; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; DISEASE MODELS, ANIMAL; MALE; MICE; MICE, KNOCKOUT; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; NEUROMUSCULAR JUNCTION; RECEPTORS, CHOLINERGIC;

EID: 84857918435     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2012.01.003     Document Type: Article

References (59)

1. Alegretti A.P., Mucenic T., Merzoni J., Faulhaber G.A., Silla L.M., Xavier R.M. Expression of CD55 and CD59 on peripheral blood cells from systemic lupus erythematosus (SLE) patients. Cell. Immunol. 2010, 265:127-132.
2. Alseth E.H., Nakkestad H.L., Aarseth J., Gilhus N.E., Skeie G.O. Interleukin-10 promoter polymorphisms in myasthenia gravis. J. Neuroimmunol. 2009, 210:63-66.
3. An F., Li Q., Tu Z., Bu H., Chan C.C., Caspi R.R., Lin F. Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. 2009, 50:3778-3782.
4. Atkinson J.P., Frank M.M. Bypassing complement: evolutionary lessons and future implications. J. Clin. Invest. 2006, 116:1215-1218.
5. Bai Y., Liu R., Huang D., La Cava A., Tang Y.Y., Iwakura Y., Campagnolo D.I., Vollmer T.L., Ransohoff R.M., Shi F.D. CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. Eur. J. Immunol. 2008, 38:1877-1888.
6. Barohn R.J., Brey R.L. Soluble terminal complement components in human myasthenia gravis. Clin. Neurol. Neurosurg. 1993, 95:285-290.
7. Chamberlain-Banoub J., Neal J.W., Mizuno M., Harris C.L., Morgan B.P. Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats. Clin. Exp. Immunol. 2006, 146:278-286.
8. Christadoss P., Tuzun E., Li J., Saini S.S., Yang H. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Ann. N. Y. Acad. Sci. 2008, 1132:210-219.
9. Conti-Fine B.M., Milani M., Kaminski H.J. Myasthenia gravis: past, present, and future. J. Clin. Invest. 2006, 116:2843-2854.
10. + T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann. N. Y. Acad. Sci. 2008, 1132:193-209.
11. De Baets M., Stassen M.H. The role of antibodies in myasthenia gravis. J. Neurol. Sci. 2002, 202:5-11.
12. De Baets M., Stassen M., Losen M., Zhang X., Machiels B. Immunoregulation in experimental autoimmune myasthenia gravis-about T cells, antibodies, and endplates. Ann. N. Y. Acad. Sci. 2003, 998:308-317.
13. Dunkelberger J.R., Song W.C. Complement and its role in innate and adaptive immune responses. Cell Res. 2010, 20:34-50.
14. Engel A.G. Acquired autoimmune myasthenia gravis. Myology 2004, 1755-1789. McGraw-Hill, New York. A.G. Engel, C. Franzini-Armstrong (Eds.).
15. Fang C., Zhang X., Miwa T., Song W.C. Complement promotes the development of inflammatory T-helper 17 cells through synergistic interaction with Toll-like receptor signaling and interleukin-6 production. Blood 2009, 114:1005-1015.
16. Farkas I., Baranyi L., Ishikawa Y., Okada N., Bohata C., Budai D., Fukuda A., Imai M., Okada H. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9. J. Physiol. 2002, 539:537-545.
17. Gomez A.M., Van Den Broeck J., Vrolix K., Janssen S.P., Lemmens M.A., Van Der Esch E., Duimel H., Frederik P., Molenaar P.C., Martinez-Martinez P., De Baets M.H., Losen M. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 2010, 43:353-370.
18. Harboe M., Mollnes T.E. The alternative complement pathway revisited. J. Cell. Mol. Med. 2008, 12:1074-1084.
19. Harris C.L., Spiller O.B., Morgan B.P. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology 2000, 100:462-470.
20. Hinchliffe S.J., Spiller O.B., Rushmere N.K., Morgan B.P. Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55). J. Immunol. 1998, 161:5695-5703.
21. Huang Y.M., Kivisakk P., Ozenci V., Pirskanen R., Link H. Increased levels of circulating acetylcholine receptor (AChR)-reactive IL-10-secreting cells are characteristic for myasthenia gravis (MG). Clin. Exp. Immunol. 1999, 118:304-308.
22. Kaminski H.J., Li Z., Richmonds C., Lin F., Medof M.E. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp. Neurol. 2004, 189:333-342.
23. Kaminski H.J., Kusner L.L., Richmonds C., Medof M.E., Lin F. Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia. Exp. Neurol. 2006, 202:287-293.
24. Kusner L.L., Kaminski H.J., Soltys J. Effect of complement and its regulation on myasthenia gravis pathogenesis. Expert. Rev. Clin. Immunol. 2008, 4:43-52.
25. Li Q., Huang D., Nacion K., Bu H., Lin F. Augmenting DAF levels in vivo ameliorates experimental autoimmune encephalomyelitis. Mol. Immunol. 2009, 46:2885-2891.
26. + T regulatory cells are protected from autologous complement mediated injury by Crry and CD59. Biochem. Biophys. Res. Commun. 2009, 382:223-226.
27. Lin F., Fukuoka Y., Spicer A., Ohta R., Okada N., Harris C.L., Emancipator S.N., Medof M.E. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies. Immunology 2001, 104:215-225.
28. Lin F., Kaminski H.J., Conti-Fine B.M., Wang W., Richmonds C., Medof M.E. Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. J. Clin. Invest. 2002, 110:1269-1274.
29. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value. 1975. Neurology 1998, 51. 933 and 936 pages following.
30. Longhi M.P., Williams A., Wise M., Morgan B.P., Gallimore A. CD59a deficiency exacerbates influenza-induced lung inflammation through complement-dependent and -independent mechanisms. Eur. J. Immunol. 2007, 37:1266-1274.
31. Louboutin J.P., Navenot J.M., Rouger K., Blanchard D. S-protein is expressed in necrotic fibers in Duchenne muscular dystrophy and polymyositis. Muscle Nerve 2003, 27:575-581.
32. Luo J., Taylor P., Losen M., de Baets M.H., Shelton G.D., Lindstrom J. Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity. J. Neurosci. 2009, 29:13898-13908.
33. Ma X.W., Chang Z.W., Qin M.Z., Sun Y., Huang H.L., He Y. Decreased expression of complement regulatory proteins, CD55 and CD59, on peripheral blood leucocytes in patients with type 2 diabetes and macrovascular diseases. Chin. Med. J. (Engl) 2009, 122:2123-2128.
34. Mantegazza R., Bonanno S., Camera G., Antozzi C. Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr. Dis. Treat. 2011, 7:151-160.
35. Medof M.E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J. Exp. Med. 1984, 160:1558-1578.
36. Miwa T., Song W.C. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int. Immunopharmacol. 2001, 1:445-459.
37. Morgan B.P., Chamberlain-Banoub J., Neal J.W., Song W., Mizuno M., Harris C.L. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin. Exp. Immunol. 2006, 146:294-302.
38. Mu L., Sun B., Kong Q., Wang J., Wang G., Zhang S., Wang D., Liu Y., An H., Li H. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology 2009, 128:e826-836.
39. Nakano S., Engel A.G. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 1993, 43:1167-1172.
40. Navenot J.M., Villanova M., Lucas-Heron B., Malandrini A., Blanchard D., Louboutin J.P. Expression of CD59, a regulator of the membrane attack complex of complement, on human skeletal muscle fibers. Muscle Nerve 1997, 20:92-96.
41. Poea-Guyon S., Christadoss P., Le Panse R., Guyon T., De Baets M., Wakkach A., Bidault J., Tzartos S., Berrih-Aknin S. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J. Immunol. 2005, 174:5941-5949.
42. Qin X., Ferris S., Hu W., Guo F., Ziegeler G., Halperin J.A. Analysis of the promoters and 5'-UTR of mouse Cd59 genes, and of their functional activity in erythrocytes. Genes Immun. 2006, 7:287-297.
43. Qin X., Hu W., Song W., Grubissich L., Hu X., Wu G., Ferris S., Dobarro M., Halperin J.A. Generation and phenotyping of mCd59a and mCd59b double-knockout mice. Am. J. Hematol. 2009, 84:65-70.
44. Ramaglia V., Hughes T.R., Donev R.M., Ruseva M.M., Wu X., Huitinga I., Baas F., Neal J.W., Morgan B.P. C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc. Nat. Acad. Sci. U. S. A. 2012, 109:965-970.
45. Romi F., Kristoffersen E.K., Aarli J.A., Gilhus N.E. The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo. J. Neuroimmunol. 2005, 158:191-194.
46. Sahashi K., Engel A.G., Lambert E.H., Howard F.M. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J. Neuropathol. Exp. Neurol. 1980, 39:160-172.
47. Shandley S., Martinez S., Krolick K. IL-4 receptor as a bridge between the immune system and muscle in experimental myasthenia gravis I: up-regulation of muscle IL-15 by IL-4. Clin. Immunol. 2009, 132:246-256.
48. Sheng J.R., Li L.C., Prabhakar B.S., Meriggioli M.N. Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis?. Muscle Nerve 2009, 40:279-286.
49. Sivasankar B., Donev R.M., Longhi M.P., Hughes T.R., Davies R., Cole D.S., Morgan B.P., Marchbank K.J. CD59a deficient mice display reduced B cell activity and antibody production in response to T-dependent antigens. Mol. Immunol. 2007, 44:2978-2987.
50. Souroujon M.C., Brenner T., Fuchs S. Development of novel therapies for MG: studies in animal models. Autoimmunity 2010, 43:446-460.
51. Terstappen L.W., Nguyen M., Lazarus H.M., Medof M.E. Expression of the DAF (CD55) and CD59 antigens during normal hematopoietic cell differentiation. J. Leukoc. Biol. 1992, 52:652-660.
52. Tuzun E., Saini S.S., Morgan B.P., Christadoss P. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis. J. Neuroimmunol. 2006, 181:29-33.
53. Tuzun E., Huda R., Christadoss P. Complement and cytokine based therapeutic strategies in myasthenia gravis. J. Autoimmun. 2011, 37:136-143.
54. Willcox N., Leite M.I., Kadota Y., Jones M., Meager A., Subrahmanyam P., Dasgupta B., Morgan B.P., Vincent A. Autoimmunizing mechanisms in thymoma and thymus. Ann. N. Y. Acad. Sci. 2008, 1132:163-173.
55. Wu B., Goluszko E., Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. Curr. Protoc. Immunol. 2001, Chapter 15. Unit 15 18.
56. Wu G., Hu W., Shahsafaei A., Song W., Dobarro M., Sukhova G.K., Bronson R.R., Shi G.P., Rother R.P., Halperin J.A., Qin X. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ. Res. 2009, 104:550-558.
57. Wu G., Chen T., Shahsafaei A., Hu W., Bronson R.T., Shi G.P., Halperin J.A., Aktas H., Qin X. Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice. Circulation 2010, 121:1338-1346.
58. Yapici Z., Tuzun E., Altunayoglu V., Erdogan A., Eraksoy M. High interleukin-10 production is associated with anti-acetylcholine receptor antibody production and treatment response in juvenile myasthenia gravis. Int. J. Neurosci. 2007, 117:1505-1512.
59. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 2009, 9:729-740.